The EPS projection of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for quarter ended 2016-09-30 is $2.07. Last week, the EPS forecast was $2.07 against target of $2.07, a month earlier. Two months ago, this estimate was $2.07 versus forecast of $2.07 three months earlier, implying a deviation of 0%.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 3, and 1, correspondingly.
EPS estimate downgrade for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the preceding 30, 120, 60 and 90 days were 0, 1, 0, and 1, correspondingly.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EPS target for the quarter closed 1 was $2.07, based on 3 recommendations. As reported on 2016-05-10 the EPS was $1.87. The change was $0.56, implying a percentage deviation of 42.75%. The projections showed a standard deviation of 0.1.
Quarterly Sales Estimates
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) yearly sales prediction for the fiscal 2016 stands at $417.051 and the median estimate is at $418.207. Almost 4 analysts issued sales target.
Highest sales target is $422.7 while the lowest target is $409.09 showing standard deviation of 5.716%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of -0.826%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that the deviation in forecast was 1.624%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...